Key result
Transcatheter iASD closure was required in 1% of patients undergoing transcatheter edge-to-edge repair with the MitraClip system, predominantly due to hypoxia or right-sided heart failure.
Why the study?
When and for whom do we need to close an iatrogenic atrial septal defect after MitraClip?
Highlights the clinical dilemma and lack of guidelines regarding the routine closure of iatrogenic atrial septal defects following transcatheter edge-to-edge repair with MitraClip.
Transcatheter mitral valve edge-to-edge repair as an alternative to mitral valve surgery in a selected highrisk cohort has proven to be safe and effective for improving mitral regurgitation (MR). 1 TEER with the MitraClip system was approved in 2016 by the PMDA in Japan and widely used in with degenerative MR with a pro-T ransseptal puncture has become increasingly common in interventional cardiology, including mitral valve intervention, left atrial appendage closure, and catheter ablation. Iatrogenic atrial septal defect (iASD) is an obligatory consequence of this procedure, but closure following MitraClip therapy is not routinely performed for all iASD, and currently no guidelines exist for managing this condition. When and for whom do we need to close an iASD after MitraClip?
No takes yet. Share an insight, caveat, or question.
Hiroshi Ueno (2022) conducted an editorial in Severe mitral regurgitation undergoing transcatheter edge-to-edge repair (TEER) with MitraClip. Transcatheter iASD closure was evaluated on Prevalence of iatrogenic atrial septal defect (iASD) requiring transcatheter closure. Transcatheter iASD closure was required in 1% of patients undergoing transcatheter edge-to-edge repair with the MitraClip system, predominantly due to hypoxia or right-sided heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: